Experience with Rituximab from observational studies US POMS cohort In 56 patients 62% reduction in relapses when compared with first-line injectables SWEDISH POMS cohort 14 patients, median period of 23.6 months; stable disease was observed in 13/14 patients (93%) Side effects were similar with infusion-related reactions being the most common, followed by rashes and fever
POMS: pediatric onset multiple sclerosis Krysko KM, et al. Ann Neurol. 2020;88(1):42–55; Salzer J, et al. J Neurol. 2016 Feb;263(2):322-326
